Cooper Companies (COO) Q2 2025: MyDay, Myopia, and Surgical Devices Propel 7% Organic Growth Despite Fertility Slowdown
Cooper Companies delivered 7% organic revenue growth in Q2, fueled by daily silicone hydrogel lenses and surgical devices, while proactively tightening guidance amid persistent inventory and fertility headwinds. Management is leaning into product launches and operational leverage to drive share gains, but is resetting expectations to align with a return to pre-pandemic market growth rates and macro pressures in fertility. The strategic focus remains on expanding premium lens penetration, accelerating myopia management, and sustaining margin improvement in a more normalized demand environment.
Summary
- Premium Lens Expansion Accelerates: MyDay and MySite portfolios saw robust uptake, supported by increased fitting activity and new launches.
- Fertility Softness Persists: Asia-Pacific and capital equipment delays weighed on surgical growth, prompting a recalibration of segment expectations.
- Margin Leverage Remains a Bright Spot: Operational efficiencies and investment discipline are driving sustained margin gains despite softer top-line outlook.
Performance Analysis
Cooper Companies reported consolidated revenue of $1.002 billion, up 6% as reported and 7% organically, with both CooperVision (CVI, contact lenses) and CooperSurgical (CSI, women’s health and fertility devices) contributing. CVI delivered $670 million in revenue (5% reported, 7% organic), led by double-digit growth in daily silicone hydrogel lenses—MyDay and Clarity—and strong expansion in myopia management, particularly MySite, which grew 35%. Segment growth was broad-based across Americas, EMEA, and Asia-Pacific, with premium products and fitting activity gaining traction.
CSI posted $333 million in revenue (8% reported, 7% organic), with surgical devices and Paragard intrauterine device outpacing expectations, but fertility growth lagged at 3% due to ongoing softness in Asia-Pacific and delayed capital purchases. Gross margin improved to 68%, and operating margin rose to 24.9%, reflecting efficiency gains and OpEx leverage. Free cash flow was seasonally low at $18 million, but management reiterated confidence in a strong second-half rebound. Share repurchases totaled $40.6 million, indicating continued capital allocation discipline.
- Premium Daily Lenses Drive Growth: MyDay and Clarity portfolios, including multifocal and toric variants, led the segment, supported by expanded fitting sets and new launches.
- Myopia Management Scales: MySite crossed a $100 million run rate, with fitting activity accelerating and new promotional strategies boosting adoption.
- Fertility Segment Under Pressure: Market softness, especially in Asia-Pacific and delayed clinic investments, tempered CSI growth despite resilience in surgical and Paragard lines.
Despite outperforming the market in core lens categories and surgical devices, management acknowledged persistent inventory headwinds and industry normalization, leading to a conservative recalibration of full-year guidance.
Executive Commentary
"We're controlling what we can by executing well, including taking share, delivering leverage, launching products, and completing capacity expansion projects... We remain very bullish on this product family as we increase availability in new markets and in new channels to capitalize on opportunities."
Al White, President and CEO
"Operating expenses increased 6%, but declined as a percent of revenue to 43.1%, driven by leverage in several functional areas as prior investment activity continues to yield positive returns... We're increasing the midpoint of guidance by 10 cents, passing along the positive impact of currency and our Q2 beat offset by tariffs."
Brian Andrews, Chief Financial Officer
Strategic Positioning
1. Premium Daily Lenses and Myopia Management
CooperVision’s strategy centers on expanding its daily silicone hydrogel portfolio—MyDay and Clarity— with aggressive fitting set deployments, new launches (such as MyDay Energist in Canada), and parameter expansions. The company is also scaling its myopia management platform, MySite, through innovative pricing models and initial free trial promotions to lower adoption barriers. These moves are designed to capture share from both new and existing accounts, with a focus on premium modalities and high-retention categories.
2. Surgical Devices and Paragard Outperformance
CSI’s office and surgical portfolio posted double-digit growth, led by minimally invasive gynecological devices and labor and delivery products, as well as the Paragard IUD. The recent OBP Surgical acquisition (single-use lighted retractors) delivered 31% growth, reinforcing CSI’s commitment to innovation and margin accretion. However, the segment is balancing outperformance in devices with ongoing fertility market softness, requiring a more nuanced growth outlook.
3. Operational Leverage and Margin Expansion
Cooper continues to benefit from operational efficiency initiatives, with prior investments in manufacturing, distribution, and packaging now yielding cost per unit reductions and OpEx leverage. This is supporting margin expansion even as revenue guidance is reset, and management is signaling ongoing discipline in both cost management and capital allocation—evident in continued share repurchases and debt reduction priorities.
4. Inventory and Channel Dynamics
Management flagged persistent channel inventory contraction, with both distributors and consumers holding lower stock levels and shifting to shorter purchasing cycles (three to six months vs. annual). This dynamic is expected to pressure reported growth throughout the year, even as underlying fitting activity and product demand remain healthy.
5. Pricing Power and Tariff Mitigation
Industry pricing remains solid, with Cooper and peers considering inflation-linked price increases to offset cost pressures, including tariffs. The company expects a $4 million tariff headwind this year and is evaluating both pricing and supply chain actions to mitigate a potential 3% earnings impact in fiscal 2026 if tariffs persist. The ability to pass through price increases is viewed as a key lever to sustain margins in a volatile macro environment.
Key Considerations
This quarter underscores the company’s ability to drive premium product growth and operational leverage, while acknowledging the need for conservative planning in a more normalized market environment. Investors should weigh the following:
Key Considerations:
- Premium Mix Shift: Daily silicone hydrogel and myopia management are driving mix improvement and margin accretion, with MyDay and MySite at the forefront.
- Inventory and Consumption Disconnect: Channel inventory contraction is masking underlying demand strength, leading to softer reported growth versus fitting activity data.
- Fertility Market Volatility: Asia-Pacific and capital spending delays are weighing on CSI’s fertility segment, with management signaling a low single-digit industry growth outlook for the year.
- Operational Discipline: Efficiency gains from prior investment are supporting margin expansion, enabling the company to absorb FX and tariff headwinds while maintaining earnings growth.
- Tariff and Pricing Dynamics: The company is preparing to use both pricing and supply chain flexibility to manage anticipated tariff impacts in fiscal 2026.
Risks
Key risks include ongoing channel inventory contraction, which could continue to suppress reported revenue despite healthy underlying demand, and persistent softness in fertility, especially in Asia-Pacific and capital equipment. Tariff escalation and FX volatility present further earnings headwinds, while competitive dynamics in premium lens categories and potential consumer trade-down remain watchpoints. Management’s more conservative guidance reflects these uncertainties, but a rapid reversal in macro or inventory trends could alter the outlook.
Forward Outlook
For Q3, Cooper expects:
- Organic growth for both CVI and CSI to be below full-year guidance ranges, with a stronger Q4 anticipated as new product launches and promotional activity ramp up.
- Continued inventory pressure and moderate headwinds from MySite promotional trials in Q3, followed by acceleration in Q4.
For full-year 2025, management raised the midpoint of revenue and EPS guidance:
- Revenue: $4.11 to $4.15 billion (5% to 6% organic growth).
- Non-GAAP EPS: $4.05 to $4.11 (10% to 11.5% YoY growth).
- Free cash flow: $350 to $400 million, with a focus on debt reduction and opportunistic buybacks.
Management highlighted:
- Premium lens launches and MySite adoption as key drivers for Q4 acceleration.
- Tariff mitigation and pricing flexibility as tools to manage cost headwinds in fiscal 2026.
Takeaways
Cooper Companies is navigating a return to normalized industry growth, leveraging premium product launches, myopia management, and operational discipline to sustain margin expansion and share gains.
- Premium Portfolio Momentum: MyDay and MySite are set to drive outperformance, with fitting activity and private label expansion underpinning future growth.
- Fertility and Inventory Headwinds: Persistent softness in fertility and ongoing channel inventory resets are tempering near-term growth but are not masking underlying demand strength.
- Margin and Capital Discipline: Operational leverage and prudent capital allocation are supporting earnings growth and positioning Cooper for resilience as the macro and industry backdrop evolves.
Conclusion
Cooper Companies delivered on its premium product and operational efficiency strategies, offsetting market normalization and fertility headwinds with disciplined execution and share gains. The company’s conservative guidance reset reflects a pragmatic approach to ongoing inventory and macro risks, while its strategic levers in premium lenses and myopia management set the stage for long-term value creation.
Industry Read-Through
Cooper’s results and commentary signal a broader return to pre-pandemic growth rates in the vision care and women’s health device industries, with inventory contraction and macro caution tempering reported results across the sector. The resilience of premium product categories, ongoing pricing power, and operational leverage are key differentiators for leading players, while persistent volatility in fertility and capital equipment demand may weigh on industry-wide growth. Tariff and FX dynamics remain a cross-industry watchpoint, with supply chain flexibility and pricing discipline emerging as critical tools for margin preservation. Investors should monitor inventory trends, premium mix shifts, and the pace of new product adoption as leading indicators for sector performance.